Monopar has been granted in the U.S. and in various countries around the world a patent for antibodies that target uPAR. Monopar has also been granted patents to the MNPR-101 (huATN-658) binding epitope in the U.S., Europe and Japan. Monopar is currently prosecuting this patent in other countries around the world to further protect MNPR-101 (huATN-658).
Validive (clonidine hydrochloride) was designated as an Orphan Medicinal Product for the prevention of severe oral mucositis induced by radio-chemotherapy in head and neck cancer patients in the European Union, enabling optimization of the product’s development plan in terms of cost and duration, as well as strengthening its protection (market exclusivity).
In March 2015, the Japanese Patent Office issued a new patent on Validive. In addition to granted patents in China, South Korea and Singapore, this grant from Japanese authorities significantly strengthens the value of this strategic orphan oncology asset for the Asian market.
In June 2015, the U.S. Patent and Trademark Office (USPTO) allowed a patent covering Validive in the U.S. The U.S. claims cover a new use of clonidine, the active pharmaceutical ingredient of Validive, in the treatment of oral mucositis. Importantly, this patent also covers the use of the mucobuccal adhesive tablet (MBT) formulation of clonidine.